We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

1 hedge funds and large institutions have $918K invested in Jounce Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less capital invested

Capital invested by funds: $64.1M → $918K (-$63.1M)

99% less funds holding

Funds holding: 84 → 1 (-83)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 83

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-83
Holders Change %
-98.81%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
83
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$9.81M
2
DTC
Deep Track Capital
Connecticut
-$7.88M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$5.85M
4
BlackRock
BlackRock
New York
-$4.71M
5
OM
Opaleye Management
Massachusetts
-$4.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
OM
1
Opaleye Management
Massachusetts
$918K -$4.21M -2,210,056 -77%
TCM
2
Tang Capital Management
California
– -$9.81M -5,300,087 Closed
DTC
3
Deep Track Capital
Connecticut
– -$7.88M -4,259,653 Closed
Tudor Investment Corp
4
Tudor Investment Corp
Connecticut
– -$5.85M -3,160,841 Closed
BlackRock
5
BlackRock
New York
– -$4.71M -2,546,289 Closed
Vanguard Group
6
Vanguard Group
Pennsylvania
– -$3.9M -2,107,305 Closed
EAM
7
Erste Asset Management
Austria
– -$2.89M -1,559,587 Closed
JP Morgan Chase
8
JP Morgan Chase
New York
– -$2.1M -1,136,847 Closed
BCM
9
BML Capital Management
Indiana
– -$2.01M -1,087,961 Closed
ACM
10
Ardent Capital Management
Ohio
– -$1.71M -923,463 Closed
State Street
11
State Street
Massachusetts
– -$1.49M -807,443 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$1.42M -767,117 Closed
BCM
13
Beryl Capital Management
California
– -$1.13M -610,831 Closed
AI
14
Arena Investors
New York
– -$1.13M -610,639 Closed
Renaissance Technologies
15
Renaissance Technologies
New York
– -$1.07M -581,300 Closed
GF
16
Gabelli Funds
New York
– -$974K -526,281 Closed
Millennium Management
17
Millennium Management
New York
– -$925K -500,000 Closed
Deutsche Bank
18
Deutsche Bank
Germany
– -$836K -452,119 Closed
GCIA
19
Gabelli & Co Investment Advisers
New York
– -$786K -425,100 Closed
E
20
Ergoteles
New York
– -$740K -400,000 Closed
Northern Trust
21
Northern Trust
Illinois
– -$601K -324,786 Closed
OFM
22
Omega Fund Management
Massachusetts
– -$510K -275,513 Closed
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
– -$489K -264,270 Closed
PCM
24
PenderFund Capital Management
British Columbia, Canada
– -$616K -246,310 Closed
MSAM
25
Moloney Securities Asset Management
Missouri
– -$451K -243,950 Closed
1
2 3 4

JNCE Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2023, worth a combined $918K — down 99% from $64.1M a quarter earlier.

Sellers outnumbered buyers: 83 funds closed out of JNCE and 0 opened new positions — a net loss of 83 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Tang Capital Management, exiting entirely with an estimated $9.81M sold.

  • 1 institutional investor held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2023, down from 84 in Q1 2023.
  • Funds reported $918K of Jounce Therapeutics, Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2023 and 83 closed out, a net change of -83 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2023 was Tang Capital Management, an estimated $9.81M sold.

Based on aggregated 13F filings for Q2 2023.